Cargando…

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands

OBJECTIVE: The purpose of this study was to estimate the cost-effectiveness of memantine relative to standard care in patients with moderate-to-severe Alzheimer’s disease in the Netherlands. METHODS: A country-adapted five-year Markov model simulated disease progression through a series of states, d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoogveldt, Bart, Rive, Benoît, Severens, Johan, Maman, Khaled, Guilhaume, Chantal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148924/ https://www.ncbi.nlm.nih.gov/pubmed/21822384 http://dx.doi.org/10.2147/NDT.S19239

Ejemplares similares

Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease
por: Rive, Benoît, et al.
Publicado: (2013)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France
por: Touchon, Jacques, et al.
Publicado: (2013)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
por: Puangthong, Umamon, et al.
Publicado: (2009)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)

Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis(1)
por: Yunusa, Ismaeel, et al.
Publicado: (2021)

Erratum to: Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis
Publicado: (2021)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease
por: Chang, Wenguang, et al.
Publicado: (2018)

Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer’s Disease, In Silico Trials
por: Świetlik, Dariusz, et al.
Publicado: (2022)

Update on the use of memantine in Alzheimer’s disease
por: van Marum, Robert J
Publicado: (2009)

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine
por: Schmidt, R, et al.
Publicado: (2008)

Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer's disease: A clinical trial
por: Zhou, Tiantian, et al.
Publicado: (2019)

Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease
por: Marotta, Giambattista, et al.
Publicado: (2020)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Memantine-induced Myoclonus in a Patient with Alzheimer Disease
por: Murgai, Aditya A., et al.
Publicado: (2015)

Memantine prodrug as a new agent for Alzheimer’s Disease
por: Sestito, Simona, et al.
Publicado: (2019)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

Memantine Attenuates Alzheimer’s Disease-Like Pathology and Cognitive Impairment
por: Wang, Xiaochuan, et al.
Publicado: (2015)

Effectiveness and safety of generic memantine hydrochloride manufactured in China in the treatment of moderate to severe Alzheimer's disease: a multicenter, double-blind randomized controlled trial
por: Zhu, Minjie, et al.
Publicado: (2013)

Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity
por: Koola, Maju Mathew, et al.
Publicado: (2018)

Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan
por: Nakamura, Yu, et al.
Publicado: (2014)

Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
por: Atri, Alireza, et al.
Publicado: (2015)

An Open-Label Exploratory Study with Memantine: Correlation between Proton Magnetic Resonance Spectroscopy and Cognition in Patients with Mild to Moderate Alzheimer's Disease
por: Gordon, Marc L., et al.
Publicado: (2012)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization
por: Sánchez-López, Elena, et al.
Publicado: (2018)

The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: a meta-analysis
por: Kishi, Taro, et al.
Publicado: (2017)

Study of the Neuroprotective Effects of Memantine in Patients with Mild to Moderate Ischemic Stroke
por: Kafi, Hamidreza, et al.
Publicado: (2014)

A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers
por: Boinpally, Ramesh, et al.
Publicado: (2015)

Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer’s Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2018)

False recognition in a mouse model of Alzheimer’s disease: rescue with sensory restriction and memantine
por: Romberg, Carola, et al.
Publicado: (2012)

Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease
por: Belitskaya-Lévy, Ilana, et al.
Publicado: (2018)

PT592. Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-analysis
por: Matsunaga, Shinji, et al.
Publicado: (2016)

Therapeutic efficacy of novel memantine nitrate MN‐08 in animal models of Alzheimer’s disease
por: Wu, Liangmiao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mu95gvge5hpqeatd9pv9e79oe2